XTX Topco’s Curanex Pharmaceuticals CURX Stock Holding History

XTX Topco’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,564	Closed	-$26.2K	–	4888
2026 Q1	$26.2K	Buy	2,564 +445	+21%	+$3.34K	﹤0.01%	3485
2025 Q4	$14K	Buy	+2,119	New	+$23.3K	﹤0.01%	3136

Other funds holding CURX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco's CURX Position: Q2 2026 in Review

XTX Topco sold out of Curanex Pharmaceuticals (CURX) in Q2 2026, closing a stake of 2,564 shares — an estimated $26.2K sold.

XTX Topco first reported a position in CURX in Q4 2025 and held it in 2 quarters. The position peaked at $26.2K in Q1 2026. 11 funds tracked by Wall St. Rank hold CURX as of Q2 2026.

XTX Topco reported no remaining Curanex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 2,564 Curanex Pharmaceuticals shares in Q2 2026, an estimated $26.2K.
XTX Topco first reported a position in Curanex Pharmaceuticals in Q4 2025 and held it in 2 quarters.
XTX Topco's Curanex Pharmaceuticals position peaked at $26.2K in Q1 2026.
11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.